AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
AstraZeneca autoimmune treatment meets trial endpoint
5 May 2022 08:42
(Sharecast News) - AstraZeneca said its treatment for an autoimmune disease that attacks the central nervous system had met a primary endpoint in a phase 3 trial.
-
AstraZeneca's Imfinzi granted priority review in the US
4 May 2022 07:42
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that a supplemental biologics license application for its Imfinzi asset, in combination with standard-of-care chemotherapy, had been accepted and...
-
AstraZeneca reiterates guidance after first quarter growth
29 April 2022 08:23
(Sharecast News) - AstraZeneca said on Friday that its total revenue for the first quarter surged 60% to $11.39bn (£9.07bn), with growth across the company seeing it reiterate its full-year guidance.
-
Astrazeneca's Ultomiris receives FDA approval
28 April 2022 09:16
(Sharecast News) - Drugmaker AstraZeneca's Ultomiris asset has been approved in the US for adults with generalised myasthenia gravis.
-
AstraZeneca's Enhertu granted FDA breakthrough therapy designation
27 April 2022 08:34
(Sharecast News) - Drugmaker AstraZeneca's Enhertu candidate has been granted breakthrough therapy designation in the US for adult patients with HER2-low metastatic breast cancer.
-
FDA accepts priority review application for AstraZeneca's tremelimumab
25 April 2022 07:28
(Sharecast News) - Drugmaker AstraZeneca said on Monday that an application for priority review of its tremelimumab asset had been accepted by the US Food and Drug Administration.
-
AstraZeneca's Enhertu to be reviewed by FDA following DESTINY-Lung01 trial
19 April 2022 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Enhertu candidate had been granted priority review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung...
-
Berenberg raises target price on AstraZeneca
12 April 2022 10:18
(Sharecast News) - Analysts at Berenberg raised their target price on AstraZeneca shares from £100 to £120 on Tuesday, stating the stock was now "hot to trop".
-
JP Morgan ups AstraZeneca target price on potential for oncology pipeline
7 April 2022 14:27
(Sharecast News) - Analysts at JP Morgan hiker their target price for shares of AstraZeneca and pointed to the potential for "significant" future upward revisions to analysts' estimates for...
-
Deutsche Bank hikes AstraZeneca target price despite rising rate environment
6 April 2022 11:07
(Sharecast News) - Analysts at Deutsche Bank hiked their target price for shares of AstraZeneca, telling clients they saw no reason to tilt towards so-called 'value' names in the space and away...
-
AstraZeneca's Ondexxya receives Japanese approval
29 March 2022 07:14
(Sharecast News) - Drugmaker AstraZeneca revealed on Tuesday that its Ondexxya asset had become the first approved medicine in Japan to specifically reverse the anticoagulant effect of Factor Xa inhibitors,...
-
AstraZeneca Covid drug gets EU approval
28 March 2022 07:19
(Sharecast News) - The European Union has given marketing approval to AstraZeneca's Evusheld coronavirus medicine for adults and children over 12 years old, the company said on Monday.
Company announcements Announcements
-
Director/PDMR Shareholding
20 May 2022 16:00
AstraZeneca
-
Appointment of joint corporate brokers
9 May 2022 13:00
AstraZeneca
-
Director/PDMR Shareholding
6 May 2022 16:00
AstraZeneca
-
Enhertu approved in US for 2L HER2+ breast cancer
5 May 2022 07:10
AstraZeneca
-
Farxiga HFpEF Phase III trial met primary endpoint
5 May 2022 07:05
AstraZeneca
-
Ultomiris NMOSD Ph. III trial met primary endpoint
5 May 2022 07:00
AstraZeneca
-
Imfinzi combo granted Priority Review for BTC
4 May 2022 07:00
AstraZeneca
-
Total Voting Rights
3 May 2022 15:00
AstraZeneca
-
Result of AGM
29 April 2022 17:30
AstraZeneca
-
AstraZeneca plans new R&D centre in Massachusetts
29 April 2022 07:05
AstraZeneca
-
First quarter 2022 results
29 April 2022 07:00
AstraZeneca
-
Ultomiris approved in the US for adults with gMG
28 April 2022 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.